Investor Presentaiton

Investor presentation First three months of 2017 Slide 66 XultophyⓇ showed significant reduction of hypoglycaemic events and weight loss vs basal-bolus in phase 3b study DUAL VII phase 3b trial design 506 patients with type 2 diabetes IDegLira + metformin insulin glargine U100 + insulin aspart + metformin 26 weeks Randomisation (1:1) End of treatment Trial objective • To confirm the efficacy of XultophyⓇ versus basal-bolus therapy in terms of glycaemic control BMI: Body Mass Index Key inclusion criteria: Adults with type 2 diabetes and BMI ≤40kg/m2; HbA1c 7.0-10.0% and current basal insulin therapy 20-50 units insulin glargine U100 + metformin per day Key results and next steps • XultophyⓇ successfully demonstrated similar glucose control compared to insulin glargine U100 in combination with insulin aspart • XultophyⓇ showed superior reduction of 89% in the rate of severe or blood glucose confirmed symptomatic hypoglycaemic episodes compared to insulin glargine U100 in combination with insulin aspart • XultophyⓇ patients experienced a weight loss of 0.9 kg compared with a weight gain of 2.6 kg with the basal-bolus regimen • . At the end of the trial XultophyⓇ patients required 40 units compared to a total of 85 units with insulin glargine U100 in combination with insulin aspart Next steps: Presentation of DUAL VII data at American Diabetes Association in June 2017 changing diabetes® novo nordisk

View entire presentation